08.21.12
Almac has launched a Next Generation Sequencing (NGS) service, expanding its portfolio of services for the development of personalized medicine. This service provides support for the development of molecular tests for trial enrichment and companion diagnostic development, with a focus on targeted re-sequencing. The NGS platform expands Almac’s current services using microarray, qPCR and IHC.
Professor Paul Harkin, president and managing director of Almac’s Diagnostics business unit and Professor of Molecular Oncology at Queens University Belfast, said, “There are only a limited number of platforms that are truly amenable to diagnostic delivery. The NGS field has now moved to a point where it is a viable delivery platform and as such is a logical addition to our suite of services. We have already begun the process of developing CLIA-based assays for important mutations involved in drug response.”
Professor Paul Harkin, president and managing director of Almac’s Diagnostics business unit and Professor of Molecular Oncology at Queens University Belfast, said, “There are only a limited number of platforms that are truly amenable to diagnostic delivery. The NGS field has now moved to a point where it is a viable delivery platform and as such is a logical addition to our suite of services. We have already begun the process of developing CLIA-based assays for important mutations involved in drug response.”